Background and aims Primary Central Nervous System Lymphoma (PCNSL) is a rare disease, about 2-6.6% of all primary intracranial tumors. The incidence of PCNSL raised recently in both immunocom-promised and immunocompetent people. Surgery is usually ineffective for PCNSL and does not prolong survival because of its infiltrative growth pattern.